AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02662504
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
Trial: NCT03973554
Drug: CPP-ACP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
Trial: NCT04589234
Drug: Salmonella-IL2
RxNorm normalized name: SALMONELLA ENTERICA ENTERICA SEROVAR ENTERITIDIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
Trial: NCT04589234
Drug: FOLFIRINOX Alone (Historical Controls)
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
Trial: NCT01273441
Drug: PPI, amoxicillin, metronidazole and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
Trial: NCT01273441
Drug: PPI, amoxicillin, metronidazole and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Trial: NCT01887613
Drug: Regnite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02543073
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
Trial: NCT04181008
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride Nasal Spray
Trial: NCT03907176
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg
Trial: NCT03907176
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg
Trial: NCT03907176
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g
Trial: NCT02063867
Drug: Arm 2: Decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Trial: NCT03869385
Drug: Albutein® 200 g/L or Plasbumin® 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
Trial: NCT01301066
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg QD
Trial: NCT02308163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03669757
Drug: LEO 134310
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
Trial: NCT03669757
Drug: LEO 134310 vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active substance: none
Trial: NCT01108731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study.
Trial: NCT01894048
Drug: Qvar® (beclometasone dipropionate HFA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
Trial: NCT00465452
Drug: Continuous Release Dopamine Agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Release Dopamine Agonists
Trial: NCT01127672
Drug: corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions.
Trial: NCT04115982
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vial every 15 days during 2 months
Trial: NCT04115514
Drug: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway.
Trial: NCT00025064
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00025064
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00566982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
Trial: NCT03017872
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.
Trial: NCT01147887
Drug: Drug combination/ 26489112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
Trial: NCT01814319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral twice daily
Trial: NCT00776594
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
Trial: NCT00788931
Drug: IV LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00788931
Drug: Oral LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02141633
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
Trial: NCT00327015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Trial: NCT01470742
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
Trial: NCT00005643
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00801723
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet once daily.
Trial: NCT04353375
Drug: HMPL-453
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
Trial: NCT00134992
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00921180
Drug: Placebo and peginterferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
Trial: NCT04131322
Drug: Amgevita 40Mg Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40Mg Solution for Injection
Trial: NCT04131322
Drug: HUMIRA 40Mg Solution for Injection
RxNorm normalized name: 0.8 ML Humira 40 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40Mg Solution for Injection
Trial: NCT02995161
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
Trial: NCT02995161
Drug: SPF control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT03122678
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03122678
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00346606
Drug: Denosin® and Xyzal®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00313313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
Trial: NCT04277663
Drug: IBI310+IBI308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
Trial: NCT04277663
Drug: IBI308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
Trial: NCT01880294
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
Trial: NCT00566150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dose up to 2500mg per day, for 6 weeks.
Trial: NCT04523623
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
Trial: NCT00851552
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01813058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described.
Trial: NCT00154700
Drug: Paclitaxel,Cisplatin,5-Fu,Folic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01232504
Drug: rhGM-CSF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
Trial: NCT01232504
Drug: rhG-CSF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
Trial: NCT00386750
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04222699
Drug: Mupirocin calcium ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
Trial: NCT00431444
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00431444
Drug: Placebo oral pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00431444
Drug: Placebo intravenous (i.v.) infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03136497
Drug: 400mg ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose daily until disease progression
Trial: NCT03136497
Drug: 800mg ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose daily until disease progression
Trial: NCT03400865
Drug: HCQ/CQ and CAB combined treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
Trial: NCT00616018
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day for 10 consecutive days
Trial: NCT02336685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Trial: NCT02336685
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
Trial: NCT02265536
Drug: LY3022855
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01517451
Drug: Androgen Deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
Trial: NCT00096135
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV over 15-30 minutes
Trial: NCT04566939
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Trial: NCT00883818
Drug: azithromycin, doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g
Trial: NCT00516906
Drug: Transparent Adhesive Dressing
RxNorm normalized name: TRANSPARENT DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
Trial: NCT00096135
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rescue IV over 24 hours
Trial: NCT00096135
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00096135
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intramuscularly (IM)
Trial: NCT00096135
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00157196
Drug: Single low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
Trial: NCT02604368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule
Trial: NCT01352221
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
Trial: NCT00298623
Drug: XP13512 (GSK1838262)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02353702
Drug: Infusion of placebo during 48 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02471118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be self-administered via subcutaneous (SC) injection
Trial: NCT00004181
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02791516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injections once a month
Trial: NCT01016119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
Trial: NCT01037725
Drug: AZD5847
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal
Trial: NCT01037725
Drug: Placebo to AZD5847
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
Trial: NCT02438683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral administration
Trial: NCT03763656
Drug: Oral Hydroxyurea (100 mg/mL) Solution
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
Trial: NCT01165138
Drug: Placebo Inhaltion Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
Trial: NCT00211757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator.
Trial: NCT02645565
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
Trial: NCT02645565
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine will be given at 2 mg/kg.
Trial: NCT02048644
Drug: fostair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
Trial: NCT02048644
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matched inhaler 2puffs to be taken twice a day for 28 days
Trial: NCT05321758
Drug: Immunosuppressive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hormones, azathioprine, thalidomide
Trial: NCT02227069
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227069
Drug: M518101 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01269229
Drug: folfox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
Trial: NCT00483366
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid